Syndax Pharmaceuticals (SNDX) Return on Sales (2015 - 2026)

Syndax Pharmaceuticals' Return on Sales history runs 11 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Sales rose 4.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 7.0% increase from a year earlier, with the FY2025 full-year figure at 0.02%, up 22.0% from the prior year.
• Return on Sales climbed to 0.01% in Q1 2026 per SNDX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2026 and bottomed at 0.21% in Q2 2024.
• The 4-year median for Return on Sales is 0.02% (2023), against an average of 0.05%.
• Across the five-year window, Return on Sales decreased 20 bps in 2024 and grew 19 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.02% in 2023, then plunged by 657 bps to 0.12% in 2024, then soared by 93 bps to 0.01% in 2025, then advanced by 23 bps to 0.01% in 2026.
• Per Business Quant, the three latest SNDX Return on Sales figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).